A Comprehensive Register Of Lymphoproliferative Disorders (ReLy)

NCT07519356 | Recruiting

• 1 other identifier: ReLy
• Study Type: observational
• Target: 9,000
• Locations: 1 country
• Sites: 1

Brief Summary

The primary objective of this study is to assess the 10-year overall survival (OS) of patients with different lymphoproliferative disorders. Secondary objectives include evaluating the comorbidities and fitness of patients and their impact on treatment choices and outcomes. Additionally, the study will examine the effectiveness of various therapeutic regimens, with a particular focus on new treatments, such as chemo-free protocols, targeted drugs, and cell therapies, in order to determine the best treatment sequence for refractory and relapsed cases. The research will also investigate how clinical and biological factors influence disease progression or relapse. Another aim is to explore potential correlations between genotype, clinical phenotype, and outcomes, both at diagnosis and during various disease stages. The study will also assess the incidence of tumor lysis syndrome and other adverse events during treatment, considering how these factors might affect treatment discontinuations or dose reductions. Another objective is to evaluate the outcomes of patients who are managed with a "watch and wait" approach. Long-term toxicities and the occurrence of secondary malignancies will also be studied, alongside the analysis of healthcare costs and the resources used in patient management.

Conditions

Lymphoproliferative Disease

Outcome Measures

Primary Outcomes (1)

• To evaluate 10 year overall survival (OS) of each lymphoproliferative disorder.

  from 2002 to 2030

Study Arms (5)

LNH B

malignant tumor of the lymphatic system originating from the uncontrolled proliferation of B lymphocytes,

LNH T/NK

A heterogeneous and rare group of blood cancers (hematological malignancies) that originate from the malignant transformation of mature T lymphocytes or natural killer (NK) cells.

Hodgkin

It is a tumor of the lymphatic system, characterized by the presence of Reed-Sternberg cells, which usually originates in the lymph nodes.

Immunodeficiency-associated

conditions characterized by abnormal lymphoid tissue growth, ranging from benign to malignant lymphomas, resulting from immune dysregulation

Hystiocitic and dendritic cell neoplasms

a rare, heterogeneous group of hematologic malignancies originating from the mononuclear phagocyte system (monocytes, macrophages, and dendritic cells)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients ≥ 18 years diagnosed with and/or treated for lymphoproliferative disorders.

You may qualify if:

• Patients ≥ 18 years diagnosed with and/or treated for lymphoproliferative disorders.
• Prospective patients (or their or legal guardians) who have the ability to understand and be willing to sign a written informed consent document
• Retrospective patients who have signed the institutional document allowing the use of their data for research on their disease

You may not qualify if:

• Patients who are unable to understand informed consent document

Sponsors & Collaborators

• Fondazione IRCCS Policlinico San Matteo di Pavia: lead

Study Sites (1)

Fondazione IRCCS Policlinico San Matteo

Pavia, Lombardy, 27100, Italy

RECRUITING

MeSH Terms

Conditions

Lymphoproliferative Disorders

Condition Hierarchy (Ancestors)

Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Central Study Contacts

Luca Arcaini

CONTACT

0382501284; l.arcaini@smatteo.pv.it

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: OTHER
• Target Duration: 10 Years
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD

Study Record Dates

• First Submitted: April 2, 2026
• First Posted: April 9, 2026
• Study Start: June 9, 2022
• Primary Completion (Estimated): December 30, 2030
• Study Completion (Estimated): December 30, 2030
• Last Updated: April 9, 2026

Record last verified: 2026-04

Locations

IT (1)